China NMPA Drug Inspection - Pfizer Pharmaceuticals Co., Ltd. - Azithromycin dry suspension

China NMPA drug inspection for Pfizer Pharmaceuticals Co., Ltd. published November 16, 2021. Drug: Azithromycin dry suspension.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

China NMPA drug inspection for Pfizer Pharmaceuticals Co., Ltd. published November 16, 2021. Drug: Azithromycin dry suspension.

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Pfizer Pharmaceuticals Co., Ltd.

Inspection Date

Unknown Date

Product Type

ID: 27c41cfd-1e2f-4754-8ecd-f2c9e1cd5d00

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox